Install
Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.
- 60articles · 30d
- 17+ hour agolatest article
- Aug 15, 2026earliest in window
- 97%with images
- 212avg words
- Medical 45
- Health & Wellness 36
- Economy, Business & Finance 23
- Health 20
- Business & Industrial 19
- Science & Technology 17
- Science & Nature 7
- Finance & Business 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Nobody Is the Payer
1+ week, 1+ day ago (229+ words) 04 September 2026 | Friday | Analysis Each payer system in this story is described from its agency's own published guidance and official materials, cited in the sources note. The same question is asked of each: what in the published method could receive a…...
DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
2+ week, 17+ hour ago (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...
Samsung Biologics to Raise KRW 3 Trillion to Fund PolyPeptide Acquisition and Manufacturing Expansion
2+ week, 11+ hour ago (226+ words) 31 August 2026 | Monday | News Samsung Biologics announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion. Additionally, following the completion of Plant…...
Formosa Pharmaceuticals Files European CTA for TSY-110, Potential First Kadcyla Biosimilar in Regulated Markets
2+ week, 11+ hour ago (86+ words) 31 August 2026 | Monday | News Designed following regulatory guidance from both US and EU authorities, the upcoming trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product. This milestone advances Formosa Pharmaceuticals' and EirGenix's shared…...
South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal
3+ week, 6+ hour ago (260+ words) 24 August 2026 | Monday | News Hanmi Pharm announced that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing, and commercialization of Hanmi's novel metabolic treatment candidate, HM17321 (UCN2), for obesity and associated conditions…...
US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging
3+ week, 3+ day ago (142+ words) 21 August 2026 | Friday | News 68Ga-NYM096 is the first China-originated innovative radiopharmaceutical to receive FDA Breakthrough Therapy Designation. It is being developed as a non-invasive PET imaging agent to enable the characterization of indeterminate renal masses identified by Computed Tomography (CT) or Magnetic…...
Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline
3+ week, 3+ day ago (98+ words) 21 August 2026 | Friday | News Leveraging IPO proceeds, Ingenia is expediting clinical development across its broader pipeline: "Going public on KOSDAQ is a transformative milestone for Ingenia as we lead a paradigm shift in vascular disease treatments," said Sangyeul Han, PhD, CEO…...
Intuitive to Establish 316,000-Sq-Ft Robotic Surgery Manufacturing Facility in Penang
3+ week, 5+ day ago (216+ words) 19 August 2026 | Wednesday | News (From left to right): Mark Brosius, Executive Vice President, Chief Manufacturing and Supply Chain Officer, Intuitive, YB Sim, Deputy Minister of Investment, Trade and Industry, Malaysia; the Right Honourable Chow Kon Yew, Chief Minister of Penang and…...
Henlius, Sandoz Expand Global Biosimilars Alliance with Up to 10 New Antibody Assets
3+ week, 6+ day ago (79+ words) 18 August 2026 | Tuesday | News In April 2025, the two companies entered into an exclusive commercialization partnership for HLX13, Henlius' proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. This new agreement further deepens the existing oncology biosimilars collaboration between…...